Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Contract with US Environmental Protection Agency

Cyprotex PLC (AIM: CRX), the specialist preclinical contract research organisation today announces that the U.S. Environmental Protection Agency (EPA) has awarded the Company the contract to obtain contractor services in support of the EPA’s ongoing ToxCast Project relating to the Prioritization of Environmentally Relevant Chemicals. Cyprotex will be providing High Content Imaging Bioassay Analysis of the ToxCast Compound Library. The contract commenced on 25 April 2013 and runs for a period of five years. The delay in concluding this contract was referred to in the Chairman’s comment in the Company’s Interim Results announcement of 6 September 2012.

For further information:

Cyprotex PLC Tel: +44 (0) 1625 505 100 
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com

N+1 Singer (Nomad and broker to Cyprotex) Tel: +44 (0)20 7496 3000
Shaun Dobson
Jenny Wyllie
shaun.dobson@nplus1singer.com
jenny.wyllie@nplus1singer.com
www.nplus1singer.com

FTI Consulting Tel: +44 (0) 20 7831 3113
Simon Conway
Mo Noonan
cyprotex@fticonsulting.com
www.fticonsulting.com
 

Notes to Editors

About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close